



MERCK



ADCore Payload
Intermediates:
**Simplify Your
Payload
Synthesis**


SAFC[®]

Pharma & Biopharma Raw
Material Solutions

The Life Science business
of Merck operates as
MilliporeSigma in the
U.S. and Canada.

A New Generation of Advanced Payload Intermediates

Reduce Development Costs and Time with ADCore



Customizable, Off-the-Shelf Intermediates

Introducing ADCore, a comprehensive product line of advanced intermediates aimed at significantly reducing the time, risks, and challenges associated with ADC payload development and manufacturing.

We offer advanced intermediates for the most common payload classes:

- Dolastatins
- Pyrrolobenzodiazepines (PBDs)
- Maytansinoids

Expedite Your ADC Development

After selecting a clinical candidate, customers must develop numerous steps in-house or at a CDMO to arrive at a suitable GMP payload for use in clinical programs, leading to possible increased costs and delayed timelines. Our ADCore product line aims to address these challenges.

- DOLCore™ Intermediate
- PBDCore™ Intermediate
- MAYCore™ Intermediate

Select the right ADCore product to fit your payload synthesis needs and perform downstream development work in-house or employ our CDMO services to take full advantage of our comprehensive ADC services throughout all stages of drug development and manufacture.

Product Features


- Samples offered free of charge
- Full regulatory support
- No royalties or licensing fees
- High purity material
- Suitable for up to phase I clinical studies with process validation to support path to commercial approval
- Readily available stock to support your drug conjugation projects and accelerate your development timelines

Added value

- Reduce development costs
- Decrease supply chain complexity
- Limit the risks associated with complex, multi-step reactions


Avoid Complex Synthetic Routes

ADCore products are advanced GMP intermediates that help accelerate drug development efforts by reducing the number of development and manufacturing steps needed to produce Dolastatin, PBD, or Maytansinoid payloads.



DOLCore™ Intermediate

Synthesize dolastatin payloads faster and with less risk




Dolastatins have demonstrated both clinical and commercial success as payloads for ADCs. DOLCore™ Intermediate is a versatile and advanced intermediate that can simplify the synthesis of dolastatin-10 payloads by reducing the number of synthesis steps from 15–20 to four or fewer.

- Get market exclusivity at least 12-months sooner
- 5 g samples available free of charge
- HPLC Purity $\geq 98\%$

PBDCore™ Intermediate

Develop diverse and highly potent PBDs



Comprehensive Solutions for Your ADC

We offer comprehensive supply chain reliability from discovery to commercialization of your ADC.

This includes coordinated and collaborative services for the development, manufacturing, and testing of bulk drug substance and drug product. We offer a full range of services to support your ADC projects:

- mAb, linker, payload, conjugation development, and manufacturing services
- Analytical method development and validation
- Technology transfer and manufacturing
- Stability studies for bulk drug substance and drug product
- Regulatory support

Payload and Linker Manufacturing Capabilities

With over 35 years of industry-leading experience in conjugation, we have the expertise needed to develop and deliver your bioconjugate or ADC. Our purpose-built manufacturing facilities are designed for the handling of HPAPIs, antibodies, linkers, and for performing complex bioconjugation processes. Our new site expansion gives you access to one of the world's largest single nanogram OEL containment facility.

Manufacturing Capabilities

| QTY | Equipment | Capacity | Temp Range |
|-----|---|----------------------------------|----------------|
| 7 | HPAPI Kilo Labs: Single ng OEL containment | g to kg scale | -75 to +190 °C |
| 6 | HPAPI Kilo Labs: Containment down to 30 ng/m ³ | g to kg scale | -75 to +190 °C |
| 4 | Potent Kilo Labs: Containment down to 1 µg/m ³ | g to kg scale | -75 to +190 °C |
| 3 | HPAPI Pilot Plants: Containment down to 30 ng/m ³ | 120–800 L 3–25 kg batch | -20 to +180 °C |
| 2 | Potent Production Plants: Containment down to 1 µg/m ³ | 2,000–4,000 L 50–400 kg batch | -80 to +180 °C |

For additional information, please visit sigmaaldrich.com/services/contract-manufacturing/high-potent-apis


To place an order or receive technical assistance, please visit sigmaaldrich.com/services/contact-safc

©2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the Vibrant M, SAFC, ADC Express, ChetoSensor, ADCore, DOLCore, PBDCore and MAYCore are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

Lit. No. MK_BR9078EN 08/2022

ADC Contract Manufacturing Footprint

Comprehensive ADC Solutions from Discovery to Commercial



ChetoSensor™ Technology

A technology that solves many challenges with antibody-drug conjugates

- Increased ADC solubility, particularly for higher DAR ADCs
- Wider therapeutic index and higher drug efficacy
- Improved bioconjugation efficiency

ADC Express™ Services

Pre-clinical conjugation services for the best candidate selection

- Mini-prep scale: 10–20 mg ADC construct ± column purification
- Medium-prep scale: up to 100 mg ADC ± column purification
- Certificate of testing with key quality attributes

DM1 – Mertansine

A GMP quality payload for your drug-conjugate programs

- Samples available free of charge
- Validated analytical methods
- Free licensing and no royalty payments

Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany

